Matches in SemOpenAlex for { <https://semopenalex.org/work/W2791330442> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2791330442 endingPage "7" @default.
- W2791330442 startingPage "4" @default.
- W2791330442 abstract "Abstract Background Multiple system atrophy (MSA) is a sporadic, adult-onset and rapidly progressive neurodegenerative disorder. MSA clinically is characterized by prominent autonomic dysfunction with combinations of parkinsonism (MSA-P), cerebellar ataxia (MSA-C) and possible corticospinal signs. To date no disease-modifying treatment is available. Motor symptoms of certain patients with MSA-P, however, are somewhat responsive to dopaminergic medication. Objective To present the analysis of symptomatic treatment options on 97 patients suffering from probable MSA-P. Methods A retrospective survey was conducted on 97 patients from a specialized neurological acute care hospital, all meeting appropriate published criteria of probable MSA-P. We undertook a thorough analysis on patients’ records regarding the dopaminergic drugs and amantadine. Results Ten patients from our study cohort received no L-dopa, in the remaining 87 patients (89.69%) the mean L-dopa daily dose was 650.93 ± 289.21 mg. Fifteen study patients received ≥1000 mg of L-dopa per day. For 31 MSA-P patients (31.96%) dopamine agonists were added as a second treatment option with pramipexole and ropinirole being the most frequently used. Further, two study patients received amantadine as an alternative medication. Conclusions In the study the considerable proportion of MSA-P patients received high levels of dopaminergic medication chronically. Its efficacy on MSA is still uncertain and further studies with standardised clinical efficacy monitoring are highly welcome." @default.
- W2791330442 created "2018-03-29" @default.
- W2791330442 creator A5017772681 @default.
- W2791330442 creator A5037073501 @default.
- W2791330442 date "2018-05-01" @default.
- W2791330442 modified "2023-09-27" @default.
- W2791330442 title "Symptomatic medication of 97 patients with multiple system atrophy parkinsonian subtype: An observational study" @default.
- W2791330442 cites W1902295431 @default.
- W2791330442 cites W1969040413 @default.
- W2791330442 cites W1984432498 @default.
- W2791330442 cites W1993608820 @default.
- W2791330442 cites W2005732728 @default.
- W2791330442 cites W2031211619 @default.
- W2791330442 cites W2031443813 @default.
- W2791330442 cites W2034883940 @default.
- W2791330442 cites W2043325179 @default.
- W2791330442 cites W2068005417 @default.
- W2791330442 cites W2071243806 @default.
- W2791330442 cites W2089085990 @default.
- W2791330442 cites W2101929592 @default.
- W2791330442 cites W2103976813 @default.
- W2791330442 cites W2125766898 @default.
- W2791330442 cites W2132807198 @default.
- W2791330442 cites W2155299862 @default.
- W2791330442 cites W2340875712 @default.
- W2791330442 cites W2562001392 @default.
- W2791330442 cites W2591588444 @default.
- W2791330442 cites W4249888301 @default.
- W2791330442 doi "https://doi.org/10.1016/j.baga.2018.02.001" @default.
- W2791330442 hasPublicationYear "2018" @default.
- W2791330442 type Work @default.
- W2791330442 sameAs 2791330442 @default.
- W2791330442 citedByCount "2" @default.
- W2791330442 countsByYear W27913304422020 @default.
- W2791330442 countsByYear W27913304422022 @default.
- W2791330442 crossrefType "journal-article" @default.
- W2791330442 hasAuthorship W2791330442A5017772681 @default.
- W2791330442 hasAuthorship W2791330442A5037073501 @default.
- W2791330442 hasConcept C126322002 @default.
- W2791330442 hasConcept C187212893 @default.
- W2791330442 hasConcept C23131810 @default.
- W2791330442 hasConcept C2776525014 @default.
- W2791330442 hasConcept C2779134260 @default.
- W2791330442 hasConcept C2781172350 @default.
- W2791330442 hasConcept C71924100 @default.
- W2791330442 hasConcept C99508421 @default.
- W2791330442 hasConceptScore W2791330442C126322002 @default.
- W2791330442 hasConceptScore W2791330442C187212893 @default.
- W2791330442 hasConceptScore W2791330442C23131810 @default.
- W2791330442 hasConceptScore W2791330442C2776525014 @default.
- W2791330442 hasConceptScore W2791330442C2779134260 @default.
- W2791330442 hasConceptScore W2791330442C2781172350 @default.
- W2791330442 hasConceptScore W2791330442C71924100 @default.
- W2791330442 hasConceptScore W2791330442C99508421 @default.
- W2791330442 hasLocation W27913304421 @default.
- W2791330442 hasOpenAccess W2791330442 @default.
- W2791330442 hasPrimaryLocation W27913304421 @default.
- W2791330442 hasRelatedWork W120688742 @default.
- W2791330442 hasRelatedWork W1968317951 @default.
- W2791330442 hasRelatedWork W2127773004 @default.
- W2791330442 hasRelatedWork W2765980456 @default.
- W2791330442 hasRelatedWork W2791330442 @default.
- W2791330442 hasRelatedWork W2939064660 @default.
- W2791330442 hasRelatedWork W2976382042 @default.
- W2791330442 hasRelatedWork W2981703979 @default.
- W2791330442 hasRelatedWork W4239928413 @default.
- W2791330442 hasRelatedWork W2464797648 @default.
- W2791330442 hasVolume "12" @default.
- W2791330442 isParatext "false" @default.
- W2791330442 isRetracted "false" @default.
- W2791330442 magId "2791330442" @default.
- W2791330442 workType "article" @default.